InvestorsHub Logo
Followers 61
Posts 7537
Boards Moderated 2
Alias Born 02/10/2010

Re: JG36 post# 66065

Tuesday, 02/26/2013 2:36:23 PM

Tuesday, February 26, 2013 2:36:23 PM

Post# of 146240
I actually figure that there is a 50/50,... 40/60 chance of success here as well in the medium term. Higher probability of success over longer periods of time.

More of a question of when,... how long,... and what particular formulation/application ends up taking control.

My confidence in success here actually took a significant upswing when they came out with the data indicating that the oral form of the viricide worked as well or better in model systems as the IV version,... and both worked better than Tamiflu.

Even IF there ends up being a toxicity problem that needs to be fixed on human internal applications,... the 'Herpes Creme' formulation that was once a major point of conversation here still has a market. Externally applied formulations have a different set of critiera than ones for internal use as regards cell damage toxicity.

The leading potential product is the flucide - given. But that is not the only ligand type and potential formulation that could be put forward.

IMO - too many things would have to go wrong for too long to completely scuttle this company in the long term.

ROI,... and time to see ROI,... more debatable issues.

“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News